Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
ASCO 2023: Leukemia and Lymphoma
July 31st 2023Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
Read More
Annual Clinical Update on MDS Sees Hope in Precision Medicine, Use of Oral Therapy
July 29th 2023An overview of the 2023 recommendations on myelodysplastic syndromes by Guillermo Garcia-Mareno, MD, of MD Anderson Cancer Center, appears in the August issue of the American Journal of Hematology.
Read More
How SURPASS-CVOT Spotlights Tirzepatide for Cardiovascular Outcomes: Dr Stephen Nicholls
July 28th 2023Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, expands on the patient characteristics and potential impacts of COVID-19 on SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide.
Read More
Dr Stephen Nicholls Discusses the Systemic Effects of Incretin-Based Therapies
July 24th 2023With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, Monash University and Victorian Heart Hospital, Melbourne, Australia. discusses contributions in the space from therapies with systemwide effects.
Read More
Enhancing Oncology Model Attracts Key Practices, Leaders Who Had Success in the OCM
July 6th 2023While the final number of EOM practices will be fewer than the numbers in the OCM, the presence of Tennessee Oncology, Texas Oncology, and Northwest Medical Specialties will ensure participation of key leaders who succeeded in the OCM and have weighed in on what's needed in its replacement.
Read More
Poster Talks Explore How Policy, Payer Incentives Affect Cancer Care, Outcomes
July 3rd 2023Speakers elaborated on health care delivery and regulatory policy posters presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. This article will appear in the ASCO recap edition of Evidence-Based Oncology.
Read More
Unknown Number of Practices Drop From EOM as Deadline Nears; Billing Flaw Questioned
June 30th 2023Ahead of tonight's deadline for practices to decide whether to join the Enhancing Oncology Model, CMS published a list of participants that is already outdated. A possible flaw in the model's breast cancer methodology has some practices weighing their options.
Read More
FDA Approves Delandistrogene Moxeparvovec, First Gene Therapy to Treat Duchenne Muscular Dystrophy
June 22nd 2023The therapy, to be marketed as Elevidys, is approved for the treatment of ambulatory pediatric patients aged 4 through 5 years with DMD who have a confirmed mutation in the DMD gene.
Read More